Salarius Pharmaceuticals changes name to Decoy Therapeutics, ticker to DCOY Jan 7, 2026 08:46AM
Salarius Pharmaceuticals faces Nasdaq delisting over stock price Jan 2, 2026 05:16PM
Salarius adjourns annual meeting due to insufficient quorum Dec 19, 2025 11:13AM
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics in January Dec 18, 2025 07:51AM
Salarius teams with Texas Biomed to test avian flu inhibitors Dec 1, 2025 08:05AM


Nov 19, 2025 02:44PM Salarius corrects S&P CapIQ error about Nasdaq delisting after merger
Oct 13, 2025 08:46AM Salarius Pharmaceuticals regains full NASDAQ compliance
Aug 15, 2025 04:19PM Salarius Pharmaceuticals, Inc. (SLRX) Files $50M Mixed Shelf
Jul 14, 2025 08:32AM Salarius Pharmaceuticals receives extension to meet Nasdaq equity requirement
Jul 9, 2025 08:35AM Salarius reports studies support seclidemstat's LSD1 inhibition role
Feb 3, 2025 08:02AM Salarius Pharmaceuticals (SLRX) Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
Dec 16, 2024 06:23AM Salarius Pharmaceuticals, Inc. (SLRX) Files for 6.73M Share Offering by Selling Stockholders
Jun 12, 2024 08:00AM Salarius Pharmaceuticals (SLRX) Announces 1-for-8 Reverse Stock Split